论文部分内容阅读
目的分析在晚期食管癌治疗中奈达铂联合氟尿嘧啶的临床疗效。方法收集2013年1月至2015年1月许昌市中心医院收治的58例晚期食管癌患者为研究对象,将58例研究对象随机分为观察组与对照组,观察组给予奈达铂联合氟尿嘧啶治疗,对照组给予顺铂联合氟尿嘧啶治疗。结果观察组总有效率为68.97%,对照组为37.93%,差异有统计学意义(P<0.05)。两组不良反应发生情况比较差异未见统计学意义(P>0.05)。结论奈达铂联合氟尿嘧啶治疗晚期食管癌临床疗效显著,建议在临床上推广。
Objective To analyze the clinical efficacy of nedaplatin and fluorouracil in the treatment of advanced esophageal cancer. Methods Fifty-eight patients with advanced esophageal cancer who were admitted to Xuchang Central Hospital from January 2013 to January 2015 were enrolled. Fifty-eight subjects were randomly divided into observation group and control group. The observation group was treated with nedaplatin plus fluorouracil The control group was treated with cisplatin and fluorouracil. Results The total effective rate was 68.97% in observation group and 37.93% in control group, the difference was statistically significant (P <0.05). Adverse reactions between the two groups showed no significant difference (P> 0.05). Conclusion Nedaplatin combined with 5-Fluorouracil in the treatment of advanced esophageal cancer clinical efficacy is significant, it is recommended in the clinical promotion.